In terms of generic drug, Sino Biopharmaceutical will have more than 20 generic drugs marketed in the next 2-3 years, wherein, the number of first generics will approach 15, making it the well-deserved “king of first generics”; in terms of innovative drug, it will have more indications approved successively in the future besides anlotinib marketed last year, and its anti-PD-L1 monoclonal antibody TQB2450 is expected to be marketed in 2021.
